Accelerating Early Access to Immunotherapies for Advanced Urothelial Carcinoma

Within one year, five immunotherapies have been approved for the treatment of patients with locally advanced or metastatic urothelial cancer. The availability of these immunotherapies brings challenges to all stakeholders in the field. Additional research is needed to identify biomarkers that are pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ning, Yang‐Min, Maher, V. Ellen, Beaver, Julia A., Goldberg, Kirsten B., Blumenthal, Gideon M., Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/
https://www.ncbi.nlm.nih.gov/pubmed/29180460
http://dx.doi.org/10.1634/theoncologist.2017-0415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813751/
https://www.ncbi.nlm.nih.gov/pubmed/29180460
http://dx.doi.org/10.1634/theoncologist.2017-0415

Ejemplares similares